These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12519195)

  • 1. Glycolipid depletion in antimicrobial therapy.
    Svensson M; Frendeus B; Butters T; Platt F; Dwek R; Svanborg C
    Mol Microbiol; 2003 Jan; 47(2):453-61. PubMed ID: 12519195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate receptor depletion as an antimicrobial strategy for prevention of urinary tract infection.
    Svensson M; Platt F; Frendeus B; Butters T; Dwek R; Svanborg C
    J Infect Dis; 2001 Mar; 183 Suppl 1():S70-3. PubMed ID: 11171019
    [No Abstract]   [Full Text] [Related]  

  • 3. Glycolipid receptor depletion as an approach to specific antimicrobial therapy.
    Svensson M; Platt FM; Svanborg C
    FEMS Microbiol Lett; 2006 May; 258(1):1-8. PubMed ID: 16630247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
    Andersson U; Butters TD; Dwek RA; Platt FM
    Biochem Pharmacol; 2000 Apr; 59(7):821-9. PubMed ID: 10718340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 fimbriae deliver an LPS- and TLR4-dependent activation signal to CD14-negative cells.
    Hedlund M; Frendéus B; Wachtler C; Hang L; Fischer H; Svanborg C
    Mol Microbiol; 2001 Feb; 39(3):542-52. PubMed ID: 11169097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH; Platt FM
    Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection.
    Godaly G; Bergsten G; Hang L; Fischer H; Frendéus B; Lundstedt AC; Samuelsson M; Samuelsson P; Svanborg C
    J Leukoc Biol; 2001 Jun; 69(6):899-906. PubMed ID: 11404374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do type 1 fimbriae promote inflammation in the human urinary tract?
    Bergsten G; Wullt B; Schembri MA; Leijonhufvud I; Svanborg C
    Cell Microbiol; 2007 Jul; 9(7):1766-81. PubMed ID: 17359236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation.
    Bäckhed F; Alsén B; Roche N; Angström J; von Euler A; Breimer ME; Westerlund-Wikström B; Teneberg S; Richter-Dahlfors A
    J Biol Chem; 2002 May; 277(20):18198-205. PubMed ID: 11877427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of P fimbriae for Escherichia coli establishment and mucosal inflammation in the human urinary tract.
    Wullt B
    Int J Antimicrob Agents; 2003 Jun; 21(6):605-21. PubMed ID: 13678032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis.
    Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD
    Biochem J; 2004 Aug; 381(Pt 3):861-6. PubMed ID: 15128268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of fimbriae of Escherichia coli in urinary tract infections].
    Ishikawa S
    Hinyokika Kiyo; 1991 Sep; 37(9):953-6. PubMed ID: 1686148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of nitric oxide on adherence of P-fimbriated uropathogenic Escherichia coli to human renal epithelial cells.
    Svensson L; Säve S; Persson K
    BJU Int; 2010 Jun; 105(12):1726-31. PubMed ID: 19863519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-fimbriae trigger mucosal responses to Escherichia coli in the human urinary tract.
    Wullt B; Bergsten G; Connell H; Röllano P; Gebratsedik N; Hang L; Svanborg C
    Cell Microbiol; 2001 Apr; 3(4):255-64. PubMed ID: 11298649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
    Elliot-Smith E; Speak AO; Lloyd-Evans E; Smith DA; van der Spoel AC; Jeyakumar M; Butters TD; Dwek RA; d'Azzo A; Platt FM
    Mol Genet Metab; 2008 Jun; 94(2):204-11. PubMed ID: 18387328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of fimbriae-mediated adherence for neutrophil migration across Escherichia coli-infected epithelial cell layers.
    Godaly G; Frendéus B; Proudfoot A; Svensson M; Klemm P; Svanborg C
    Mol Microbiol; 1998 Nov; 30(4):725-35. PubMed ID: 10094621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice.
    Håversen LA; Engberg I; Baltzer L; Dolphin G; Hanson LA; Mattsby-Baltzer I
    Infect Immun; 2000 Oct; 68(10):5816-23. PubMed ID: 10992490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial glucosphingolipid expression as a determinant of bacterial adherence and cytokine production.
    Svensson M; Lindstedt R; Radin NS; Svanborg C
    Infect Immun; 1994 Oct; 62(10):4404-10. PubMed ID: 7927702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation.
    Frendéus B; Wachtler C; Hedlund M; Fischer H; Samuelsson P; Svensson M; Svanborg C
    Mol Microbiol; 2001 Apr; 40(1):37-51. PubMed ID: 11298274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the ceramide-signaling pathway in cytokine responses to P-fimbriated Escherichia coli.
    Hedlund M; Svensson M; Nilsson A; Duan RD; Svanborg C
    J Exp Med; 1996 Mar; 183(3):1037-44. PubMed ID: 8642245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.